Search

Inhibitory T Cell Receptor Peptides and Discovery Methods

USPTO granted patent US12606816B2 to Janux Therapeutics, Inc. covering inhibitory T cell receptor peptides and methods of inhibiting T cell receptor interactions with peptide-major histocompatibility complexes. The patent discloses peptides that bind to T cell receptors without requiring major histocompatibility complex assistance. Six claims are associated with this patent.